IRIS
SVICHER, VALENTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 39.454
EU - Europa 4.184
AS - Asia 1.922
OC - Oceania 101
SA - Sud America 52
AF - Africa 17
Continente sconosciuto - Info sul continente non disponibili 13
Totale 45.743
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 39.422
SG - Singapore 1.112
IT - Italia 732
DE - Germania 628
UA - Ucraina 490
IE - Irlanda 450
CN - Cina 412
SE - Svezia 411
FR - Francia 356
PL - Polonia 328
RU - Federazione Russa 283
KR - Corea 236
GB - Regno Unito 194
FI - Finlandia 140
AU - Australia 94
BE - Belgio 50
CZ - Repubblica Ceca 45
VN - Vietnam 44
JP - Giappone 32
ES - Italia 28
CA - Canada 27
NL - Olanda 23
BR - Brasile 21
HK - Hong Kong 20
IN - India 19
CL - Cile 11
CO - Colombia 10
EU - Europa 9
CH - Svizzera 8
RO - Romania 8
NZ - Nuova Zelanda 7
TR - Turchia 7
AR - Argentina 6
PK - Pakistan 6
CM - Camerun 4
KG - Kirghizistan 4
MX - Messico 4
MY - Malesia 4
A2 - ???statistics.table.value.countryCode.A2??? 3
DK - Danimarca 3
EC - Ecuador 3
KZ - Kazakistan 3
NG - Nigeria 3
TW - Taiwan 3
UG - Uganda 3
AM - Armenia 2
AT - Austria 2
BD - Bangladesh 2
GH - Ghana 2
IL - Israele 2
LK - Sri Lanka 2
MN - Mongolia 2
QA - Qatar 2
ZA - Sudafrica 2
A1 - Anonimo 1
AE - Emirati Arabi Uniti 1
AL - Albania 1
BG - Bulgaria 1
DM - Dominica 1
EG - Egitto 1
GR - Grecia 1
ID - Indonesia 1
IR - Iran 1
LB - Libano 1
MD - Moldavia 1
NO - Norvegia 1
NP - Nepal 1
OM - Oman 1
PE - Perù 1
PH - Filippine 1
SA - Arabia Saudita 1
TN - Tunisia 1
ZW - Zimbabwe 1
Totale 45.743
Salva come PNG Salva come JPEG
Città #
Woodbridge 11.094
Wilmington 10.922
Houston 8.863
Fairfield 1.450
Singapore 932
Ann Arbor 919
Chandler 848
Ashburn 590
Seattle 575
Cambridge 462
Jacksonville 417
Dublin 393
Kraków 324
Rome 291
Medford 284
Dearborn 275
Santa Clara 222
New York 212
Beijing 196
Lawrence 136
Milan 100
San Diego 97
Menlo Park 85
Mülheim 65
Zhengzhou 59
Moscow 53
Brussels 49
Munich 44
Creede 41
Helsinki 37
Palo Alto 37
San Francisco 33
London 32
Melbourne 30
Sydney 30
Boardman 29
La Veta 29
Dong Ket 28
Phoenix 28
Engelhard 26
Redwood City 26
Brno 25
University Park 25
Cedarhurst 23
Canberra 22
Falls Church 22
Council Bluffs 20
Nanjing 20
Olomouc 20
Washington 19
Bari 15
Colorado Springs 15
Hefei 15
Hong Kong 15
Mountain View 15
Verona 15
Guangzhou 14
Naples 14
Norwalk 14
Nuremberg 14
Madrid 13
Toronto 13
Los Angeles 12
Shanghai 12
St. George 12
Jinan 11
Saint Petersburg 11
San Mateo 11
Seoul 11
Hanoi 10
Kunming 10
San Jose 10
Amsterdam 9
Nanchang 9
Padova 9
Genoa 8
Kilburn 8
Tokyo 8
Wuhan 8
Auckland 7
Nürnberg 7
Stockholm 7
São Paulo 7
Auburn Hills 6
Bogotá 6
North Hollywood 6
Shenyang 6
The Dalles 6
Albano Laziale 5
Coventry 5
Fort Worth 5
Genzano di Roma 5
Hanover 5
Ho Chi Minh City 5
Indiana 5
Lappeenranta 5
Prescot 5
Barcelona 4
Buenos Aires 4
Chicago 4
Totale 41.015
Salva come PNG Salva come JPEG
Nome #
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 512
The Genotypic False Positive Rate Determined by Population V3-Sequencing can Predict the Burden of X4 Quasispecies Detected by Pyrosequencing 496
Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor 496
Therapeutic strategies towards HIV-1 infection in macrophages 472
Treatment with the fusion inhibitor enfuvirtide influences the appearance of mutations in the human immunodeficiency virus type 1 regulatory protein rev 460
Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice 455
Novel drug resistance mutations in HIV: Recognition and clinical relevance 446
Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors 446
Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression 446
Novelties in evaluation and monitoring of human immunodeficiency virus-1 infection: Is standard virological suppression enough for measuring antiretroviral treatment success? 440
Understanding HIV compartments and reservoirs 437
Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia 436
Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance. 435
Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection 434
Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro 429
Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen 429
Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure 423
Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors 423
HIV-1-associated dementia during HAART therapy 423
Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naïve to antiviral drugs. 423
Characterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients naive to the antiretroviral drugs 423
Effect of maraviroc on non-R5 tropic HIV-1: Refined analysis of subjects from the phase IIb study A4001029 421
'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing 419
Detection of high levels of Survivin-immunoglobulin M immune complex in sera from hepatitis C virus infected patients with cirrhosis 417
Characterization of novel HIV drug resistance mutations using clustering, multidimensional scaling and SVM-based feature ranking 416
Epidemiological network analysis in HIV-1 B infected patients diagnosed in Italy between 2000 and 2008 416
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 414
Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection. 412
Mechanisms underlying activity of antiretroviral drugs in HIV-1-infected macrophages: New therapeutic strategies 409
Specific HbsAg genetic determinants are associated with occult HBV infection in vivo and HbsAg detection 408
Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens 405
The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients 404
HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors 403
Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment 403
48 week outcomes of maraviroc-containing regimens following the genotypic or Trofile assay in HIV-1 failing subjects: the OSCAR Study 403
Molecular and structural aspects of clinically relevant mutations related to the approved non-nucleoside inhibitors of HIV-1 reverse transcriptase 400
Specific HBSAG Genetic- Determinants are associated with occult HBV-infection in vivo and HBSAG detection 400
Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development 398
Hepatitis B reactivation characterized by HBsAg negativity and anti-HbsAg antibodies persistence in haematopoietic stem cell transplanted patient after lamivudine withdrawal 397
Complete hbv prophylaxis withdrawal in HBsAg-positive liver transplant recipients after long-term minimal immunosuppression 395
Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors 394
Subtype analysis and mutations to antiviral drugs in HIV-1-infected patients from Mozambique before initiation of antiretroviral therapy: Results from the DREAM programme 393
Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence 392
Identification and structural characterization of novel genetic elements in the HIV-1 V3 loop regulating coreceptor usage 392
The multifactorial pathways towards resistance to the cytosine analogues emtricitabine and lamivudine: Evidences from literature 387
Temporal characterization of drug resistance associated mutations in HIV-1 protease and reverse transcriptase in patients failing antiretroviral therapy 386
Incomplete APOBEC3G/F neutralization by HIV-1 Vif mutants facilitates the genetic evolution from CCR5 to CXCR4 usage 386
Description of the L76V resistance protease mutation in HIV-1 B and "non-B" subtypes 385
Limited development and progression of resistance of HIV-1 to the nucleoside analogue reverse transcriptase inhibitor lamivudine in human primary macrophages 384
The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes 384
Detecting and understanding genetic and structural features in HIV-1 B subtype V3 underlying HIV-1 co-receptor usage 384
Highlights on HIV eradication in 2013 384
Molecular dynamics and free energy studies on the wild-type and mutated hiv-1 protease complexed with four approved drugs: Mechanism of binding and drug resistance 381
Key patterns of HBX and pre-S1/S2 mutations are involved in mechanisms underlying HBV-induced hepatocellular carcinoma in vivo 380
Comparative replication capacity of raltegravir-resistant strains and antiviral activity of the new-generation integrase inhibitor dolutegravir in human primary macrophages and lymphocytes 380
Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance 379
HIV-1 R5+ /X4- tropic viruses can be inhibited in vitro as well as in vivo by maraviroc: a refined analysis of patients enrolled in the Phase IIb study A4001029 379
Key genetic elements in HIV-1 gp120 V1,V2 and C4 domains tightly and differentially modulate gp120 interaction with the CCR5 and CXCR4 N terminus and HIV-1 antigenetic Potential 378
Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group 377
Multiple Hepatitis B Virus (HBV) Quasispecies and Immune-Escape Mutations Are Present in HBV Surface Antigen and Reverse Transcriptase of Patients with Acute Hepatitis B 377
Docking Analysis and Resistance Evaluation of Clinically Relevant Mutations Associated with the HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors Nevirapine, Efavirenz and Etravirine 376
Dynamics of NRTI resistance mutations during therapy interruption 375
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA Study Group 374
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group 372
'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing 372
Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. 371
Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen 370
The role of HIV infection in neurologic injury 370
Overlapping Structure of HBV genome and immune selecting pressure are the main driving forces for HBV evolution 369
Genetic and Structural Analysis of HIV-1 Rev Responsive Element Related to V38A and T18A Enfuvirtide Resistance Mutations 368
Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors 367
Temporal change in the use of genotypic resistance testing over the years 1999--2003 367
HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia 367
Combined analysis of the prevalence of drug-resistant Hepatitis B virus in antiviral therapy-experienced patients in Europe (CAPRE) 365
The HR2 polymorphism N140I in the HIV-1 gp41 combined with the HR1 V38A mutation is associated with a less cytopathic phenotype 363
Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximab-containing therapy 361
High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations 358
Novel reverse transcriptase mutations specifically associated with selected anti-Hbv treatment can induce alterations and stop-codons in Hbv S antigen 358
HIV-2 A-subtype gp125(C2-V3-C3) mutations and their association with CCR5 and CXCR4 tropism. 357
Overlapping structure of HBV genome and immune selection pressure are critical forces modulating HBV evolution 355
A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAART. 355
HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro 353
Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens. 351
Inhibition of dual/mixed tropic HIV-1 isolates by CCR5-inhibitors in primary lymphocytes and macrophages 351
Does residual virus replication during successful HAART lead to HIV-1 genetic evolution? 348
Genotypic tropism testing in HIV-1 proviral DNA can provide useful information at low-level viremia 348
The genotypic false positive rate determined by V3 population sequencing can predict the burden of HIV-1 CXCR4-using species detected by pyrosequencing 347
Limited development and progression of resistance of HIV-1 to the nucleoside analogue reverse transcriptase inhibitor lamivudine in human primary macrophages 345
Papillomavirus and cervical cancer: Epidemiology, genetics and prevention [Il papillomavirus umano e il cancro della cervice uterina: Epidemiologia, basi genetiche e prevenzione] 342
Signature mutations in V3 and bridging sheet domain of HIV-1 gp120 are specifically associated with dual tropism and modulate the interaction with CCR5 N-terminus 342
A recent epidemiological cluster of acute hepatitis B genotype F1b infection in a restricted geographical area of Italy 340
Dual mixed (but not X4) tropic-HIV-1 isolates can replicate in human primary macrophages and are inhibited by CCR5- inhibitors 339
Selected Amino Acid Mutations in HIV-1 B Subtype gp41 are Associated with Specific gp120v3 Signatures in the Regulation of Co-Receptor Usage 338
Key genetic elements in HIV-1 gp120 V1,V2 and C4 domains tightly and differentially modulate gp120 interaction with the CCR5 and CXCR4 N terminus and HIV-1 antigenetic Potential 337
High rates of chronic HBV genotype E infection in a group of migrants in Italy from West Africa: Virological characteristics associated with poor immune clearance 327
Impact of HIV-1 tropism on the emergence of non-AIDS events in HIV-infected patients receiving fully suppressive antiretroviral therapy 323
The novel HBx mutation F30V correlates with hepatocellular carcinoma in vivo, reduces hepatitis B virus replicative efficiency and enhances anti-apoptotic activity of HBx N terminus in vitro. 319
The Lowest X4 Geno2Pheno-False Positive Rate Is Associated with Greater CD4-Depletion 313
Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection 310
Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice 305
Totale 38.874
Salva come PNG Salva come JPEG
Categoria #
all - tutte 99.750
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 99.750
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20208.147 0 0 0 0 1.024 1.386 1.130 1.024 1.034 1.002 740 807
2020/20216.974 785 769 761 884 655 756 995 658 142 204 250 115
2021/20221.913 115 146 118 101 83 163 88 83 374 147 74 421
2022/20232.328 253 198 146 271 193 468 163 226 183 34 156 37
2023/20241.264 223 35 115 62 127 207 65 25 77 111 26 191
2024/20252.195 173 1.049 487 338 148 0 0 0 0 0 0 0
Totale 46.386